Anthony Alexander McKinney
Summary
Anthony McKinney has a unique blend of scientific and business expertise gained in over 35 years of experience in pharma/biotech. Experience in pharma sales/marketing/launch, and market research during initial 5 years and for the last 32 years, a focus on new product development. As a C-level officer McKinney has overseen manufacturing, preclinical, and clinical development groups. Involved in two drug approvals, argatroban for heparin-induced thrombocytopenia thrombosis syndrome and CONTRAVE for obesity. Inventor/co-inventor of 20 issued US patents and is a co-author on 14 academic papers/abstracts/posters. McKinney has founded several NEWCOs with successful M & A and IPO exits including Novazyme in 2001, Orexigen in 2007, and Neurovance in 2017. Unique experience in simultaneously leading two companies: Euthymics/Neurovance (2011-2017) and Ethismos/Seropeutics (2023-2025). Mr. McKinney has participated in raising private and public funding totaling over $300 million as of 2Q25.
Work Experience
ETHISMOS RESEARCH, INC. (Cambridge, Massachusetts)
Founder, President, & CEO Jun 2017 – current
- Euthymics IP acquired from former investors following Neurovance exit; novel IP for prevention and treatment of chronic pain
SEROPEUTICS, LLC (Boston, Massachusetts)
President & CEOJan 2023 – current
- Novel IP from Northeastern University; discrete pre-IND compounds for anxiety, autism, ADHD, epilepsy, and IBD
NEUROVANCE, INC. (Cambridge, Massachusetts) [Exited: sold to Otsuka, Mar 2017. Deal value: $1 billion]
Founder, President, & CEO (Dec 2011-Dec 2016); Chief Development Officer (Dec 2016-Mar 2017) Dec 2011 – Mar 2017
- Euthymics sister company; raised $45 million to advance centanafadine from pre-IND to EOP2. (ADHD NDA submission expected YE2025)
EUTHYMICS BIOSCIENCE, INC. (Cambridge, Massachusetts) [IP acquired by Ethismos, Nov 2017]
Co-Founder, President, & Chief Executive Officer Mar 2009 – Mar 2017
- Raised $30 million in series A (lead: Novartis Venture Fund) to acquire DOV Pharmaceutical and develop CNS assets
OREXIGEN THERAPEUTICS, INC. (OREX) (San Diego, California) [Exited: IPO, Apr 2007]
Consultant (June 2004-Jan 2005); COO (Jan 2005-Jul 2008); CBO (Jul 2008-Dec 2008) June 2004 – Dec 2008
- Involved in raising series B and IPO (over $240 million total). Inventor of several enabling CONTRAVE patents
NOVAZYME/GENZYME (GENZ) (Cambridge, Massachusetts) [Exited: Novazyme sold to Genzyme, Sep 2001]
April 2000 – May 2003SVP & GM, Discovery & Research Projects, Genzyme Therapeutics (May 2002–May 2003)VP, Drug Development; SVP, Pharma Operations, Genzyme (Novazyme) (Apr 2000–May 2002)
TEXAS BIOTECHNOLOGY CORP (later called ENCYSIVE/PFIZER) (Houston, Texas)(1994 – 2000)
Role in the successful development of argatroban as an anticoagulant for Heparin Induced Thrombocytopenia Thrombosis Syndrome
DU PONT MERCK PHARMACEUTICAL COMPANY (Wilmington, Delaware) (1988 – 1993)
Multiple roles and promotions
Consulting/Board/Advisory Roles
PARALLEL HEALTH (Los Angeles, California), CEO Advisor and Board Member
May 2023 – Current
POSTBIOTICS PLUS RESEARCH (Houston, Texas), CEO Advisor and Board Member
Mar 2023 – Current
INSTITUTE FOR BIOMEDICAL ENTREPRENEURSHIP (Cambridge, Massachusetts), Board Advisor
Nov 2015 – Current
Education
Master of Business Administration in Global Management
Dec 1987Thunderbird School of Global Management, Glendale, Arizona
Bachelor of Science in Microbiology (Concentration in Chemistry, Minor in History)
Dec 1985University of Oklahoma, Norman, Oklahoma
Current as of 06/29/25
Current as of 06/29/25